ANIP

ANI Pharmaceuticals Inc. - 10-Q Summary (Q2 2025)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company operating through two reportable segments: Rare Disease and Brands and Generics and Other. The period reflects the full impact of the September 2024 acquisition of Alimera Sciences, Inc., which added the ILUVIEN and YUTIQ retina franchise to the portfolio. The company operates three manufacturing facilities in the U.S. (Baudette, MN; East Windsor, NJ) and has ceased operations at its former Oakville, Canada site.

Key Financial Metrics

Note: Debt figures represent the sum of current debt ($13.2M) and non-current debt ($301.5M) plus convertible notes ($306.9M) net of deferred financing costs.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 53.1% QoQ and 48.3% YTD, driven primarily by the inclusion of Alimera products (ILUVIEN and YUTIQ) and strong growth in Cortrophin Gel (up 66% QoQ).
• Profitability: The company returned to profitability in Q2 2025 ($8.5M net income) compared to a net loss of $2.3M in Q2 2024. Operating margin improved to 6.6% from 3.7%.
• Expense Increases: Operating expenses rose significantly due to the Alimera acquisition. Selling, General, and Administrative (SG&A) expenses increased 54.8% QoQ, largely due to expanded ophthalmology sales teams and integration costs. Depreciation and amortization increased 58.4% due to the amortization of acquired intangible assets.
• Contingent Consideration: A gain of $10.8M was recognized YTD 2025 related to fair value adjustments of contingent consideration (Alimera CVRs and licensor payments), contrasting with a loss in the prior year.

Guidance, Outlook, and Risks

• Product Strategy: The company is transitioning promotional efforts in the U.S. from YUTIQ to ILUVIEN, leveraging a combined label for Diabetic Macular Edema (DME) and Non-Infectious Uveitis (NIU-PS). A prefilled syringe format for Cortrophin Gel was launched in Q2 2025.
• Generics Outlook: Management anticipates lower generic revenues in the second half of 2025 compared to the first half due to the expiration of 180-day exclusivity for Prucalopride Tablets in late June 2025.
• Capital Structure: The company maintains a $325M Term Loan A (fully drawn) and a $75M undrawn revolver under a new credit facility maturing in 2029. It also has $316.3M in 2.25% Convertible Senior Notes due 2029.
• Key Risks:
  • Regulatory: Four products are marketed without approved NDAs/ANDAs, posing potential FDA enforcement risks.
  • Legal: Ongoing litigation includes a recent jury verdict in the CG Oncology case (July 2025) where ANI was awarded no damages on unjust enrichment claims; ANI plans to appeal. Ranitidine-related litigation continues in state courts.
  • Supply Chain: Reliance on single-source suppliers for Active Pharmaceutical Ingredients (APIs) creates production vulnerability.
  • Tax Legislation: The "One Big Beautiful Bill Act" signed July 4, 2025, introduces changes to R&D capitalization and interest deductions; the company is evaluating the impact.

Investor Verification Checklist

• Alimera Integration: Verify the commercial performance of ILUVIEN and YUTIQ against the revenue milestones required for Contingent Value Rights (CVRs) payouts in 2026 and 2027.
• Generics Exclusivity: Monitor the impact of the Prucalopride exclusivity expiration on H2 2025 generic revenue projections.
• Legal Outcomes: Track the status of the appeal regarding the CG Oncology verdict and the progress of Ranitidine state court litigation.
• Debt Covenants: Review compliance with financial covenants under the New Credit Agreement and Convertible Notes, particularly given the high leverage from the Alimera acquisition.
• Regulatory Status: Confirm the status of the four products marketed without approved NDAs/ANDAs and any FDA communications regarding them.